AHSA1 Protein is a protein encoded by the AHSA1 gene that ahsa1 functions as a molecular co-chaperone:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
AHSA1 (Activator of Hsp90 ATPase Homolog 1) is a co-chaperone that stimulates the ATPase activity of Hsp90, facilitating the folding and maturation of client proteins.
| Property |
Value |
| Gene |
AHSA1 |
| UniProt |
O95433 |
| PDB |
1US7, 2C2L |
| Molecular Weight |
~38 kDa |
| Subcellular Localization |
Cytoplasm |
| Protein Family |
Hsp90 co-chaperone family (Aha1 family) |
AHSA1 is a 338-amino acid protein consisting of two main domains:
- N-terminal domain: Binds to Hsp90 and stimulates its ATPase activity
- C-terminal domain: Contains the catalytic center for ATP hydrolysis stimulation
- The protein forms a dimer that can bind to Hsp90 dimer
AHSA1 functions as a molecular co-chaperone:
- ATPase stimulation: Accelerates Hsp90 ATP hydrolysis 10-fold
- Client protein maturation: Facilitates folding of Hsp90 client proteins
- Protein quality control: Helps prevent aggregation of misfolded proteins
- Cellular proteostasis: Essential for maintaining protein homeostasis
- Hsp90-mediated tau aggregation is implicated in AD pathology
- AHSA1 levels are altered in AD brains
- Modulating Hsp90-AHSA1 interaction may affect tau pathology
- Hsp90 inhibitors are being explored for AD therapy
- Alpha-synuclein aggregation involves Hsp90 machinery
- AHSA1 may influence alpha-synuclein folding and clearance
- Hsp90 family members are elevated in PD brains
- Mutant SOD1 aggregation involves Hsp90-mediated quality control
- AHSA1 may modulate mutant SOD1 toxicity
- Hsp90 inhibition reduces SOD1 aggregation in cellular models
- Mutant huntingtin protein aggregation involves Hsp90 machinery
- Modulating co-chaperone activity may influence aggregation
- Therapeutic targeting of Hsp90 complex is being explored
- Hsp90 inhibitors: Ganetespib, Onalespib (in cancer trials)
- AHSA1 modulators: Being developed to specifically modulate co-chaperone function
- Combination therapy: Hsp90 inhibitors with proteasome inhibitors